We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

PE shop boys

13 April 2020 By Robert Cyran

The private-equity firm is sinking $2 bln into Alnylam, including buying rights to future revenue from a drug still under regulatory review. It’s a way to match Blackstone’s bulging wallet with the biotech’s hefty costs while limiting exposure to volatile equity markets.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)